AstraZeneca's tremelimumab misses again, this time in SCLC by Carly Helfand Tuesday, March 17, 2020 Here’s a familiar sentence: A combo of Imfinzi and tremelimumab missed its primary endpoint. This time, it applies to a small-cell lung cancer trial.
Imfinzi's first nod in danger after bladder cancer trial failure by Angus Liu Friday, March 6, 2020 Imfinzi, given alone or in tandem with AZ's troubled CTLA4 tremelimumab, failed against chemo in first-line bladder cancer.
AstraZeneca scores lung cancer win with Imfinzi combos by Carly Helfand Monday, October 28, 2019 After watching from the sidelines as its rivals dove into I-O’s most coveted market, AstraZeneca finally has a win in previously untreated NSCLC.
AstraZeneca's I-O duo flops another late-stage lung cancer trial by Carly Helfand Wednesday, August 21, 2019 AstraZeneca has had high hopes for its Imfinzi-tremelimumab pairing. But after a high-profile miss last year, the combo has struck out again.
AZ mines for positives in Imfinzi's failed Mystic trial by Carly Helfand Thursday, December 13, 2018 AstraZeneca felt the blow last month when key trial Mystic failed. But now that the dust has settled, it's looking for bright spots in the miss.
AZ's Mystic trial delay puts Imfinzi farther behind in NSCLC by Tracy Staton Monday, March 12, 2018 AstraZeneca's Imfinzi won't have its first-line lung cancer data till later than expected, and at a time when Merck's Keytruda is racing ahead.
Daiichi denies talk of spurned AstraZeneca buyout bid by Carly Helfand Thursday, August 31, 2017 Did Daiichi Sankyo receive a buyout bid from AstraZeneca last year? According to the Japanese drugmaker, no.
Wary investors brace for AstraZeneca’s big I-O combo reveal by Carly Helfand Thursday, June 29, 2017 Investors are prepping for AstraZeneca's forthcoming Mystic data, which could shift the I-O landscape and AZ's fortunes, too.
